Claims for Patent: 8,466,199

Summary for Patent: 8,466,199

Title:	Allyloxy and alkyloxy benzoic acid delivery agents
Abstract:	The present invention relates to pharmaceutical compounds for delivering active agents, such as biologically or chemically active agents, to a target. The invention also relates to pharmaceutical compositions comprising at least one delivery agent compound of the present invention and at least one active agent, and unit dosage forms comprising such compositions. Methods for the preparation and administration of the pharmaceutical compositions are also disclosed.
Inventor(s):	Song; Jianfeng (West Windsor, NJ)
Assignee:	Emisphere Technologies, Inc. (Roseland, NJ)
Application Number:	12/529,904
Patent Claims:	1. A pharmaceutical composition comprising: (A) a biologically active agent selected from proteins, polypeptides, peptides, hormones, polysaccharides, mucopolysaccharides, carbohydrates, and lipids; and (B) at least one delivery agent compound selected from (i) compounds of formula I ##STR00018## and pharmaceutically acceptable salts thereof, wherein n is 1, 2, 3 or 4; R1, R2 and R3 are independently hydrogen, methyl or halogen; and R4 is hydrogen, methyl, methoxy, hydroxy, halogen, acetyl, or 2-hydroxy-ethoxy; and (ii) compounds of formula III ##STR00019## wherein R is methyl, ethyl, isopropyl, propyl, butyl, allyl, 1-methylallyl, 2-methylallyl, or butenyl. 2. The pharmaceutical composition of claim 1, wherein at least one of R1-R4 of Formula I is methyl, methoxy, hydroxy, or halogen. 3. The pharmaceutical composition of claim 2, wherein at least one of R1-R4 of Formula I is chlorine or fluorine. 4. The pharmaceutical composition of claim 1, wherein at least one of R1-R4 of Formula I is chlorine or fluorine. 5. The pharmaceutical composition of claim 1, wherein the at least one delivery agent compound is selected from the group consisting of: ##STR00020## ##STR00021## ##STR00022## ##STR00023## ##STR00024## ##STR00025## and pharmaceutically acceptable salts thereof. 6. The pharmaceutical composition of claim 1, wherein the biologically active agent is selected from the group consisting of: growth hormones, human growth hormones, recombinant human growth hormones, bovine growth hormones, porcine growth hormones, growth hormone releasing hormones, growth hormone releasing factor, interferons, .alpha.-interferon, .beta.-interferon, .gamma.-interferon, interleukin-1, interleukin2, insulin, porcine insulin, bovine insulin, human insulin, human recombinant insulin, insulin-like growth factor (IGF), IGF-I, heparin, unfractionated heparin, heparinoids, dermatans, chondroitins, low molecular weight heparin, very low molecular weight heparin, ultra low molecular weight heparin, calcitonin, salmon calcitonin, eel calcitonin, porcine calcitonin, human calcitonin, erythropoietin, atrial naturetic factor, antigens, monoclonal antibodies, somatostatin, protease inhibitors, adrenocorticotropin, gonadotropin releasing hormone, oxytocin, leutinizing-hormone-releasing hormone, follicle stimulating hormone, glucocerebrosidase, thrombopoietin, filgrastim, prostaglandins, cyclosporin, vasopressin, cromolyn sodium, sodium chromoglycate, disodium chromoglycate, vancomycin, desferrioxamine, bisphosphonates, alendronate, tiludronate, etidronate, clodronate, pamidronate, olpadronate, incadronate, parathyroid hormone (PTH), fragments of PTH, anti-migraine agents, sumatriptan, almotriptan, naratriptan, rizatriptan, frovatriptan, eletriptan, BIBN-4096BS, calcitonin gene-related proteins antagonists, glucagon-like peptide 1, Argatroban, glucagon, caspofungin acetate, antimicrobials, antibiotics, anti-bacterials, anti-fungal agents, vitamins, and analogs, mimetics or polyethylene glycol (PEG)-modified derivatives of these compounds, or any combination thereof. 7. The pharmaceutical composition of claim 1, wherein the biologically active agent is selected from insulin, heparin, human growth hormone, leutinizing-hormone-releasing hormone, and caspofungin acetate. 8. The pharmaceutical composition of claim 7, wherein the composition comprises about 0.1 to 2.0 mg/kg of insulin and about 50 to 800 mg/kg of the delivery agent compound, or the composition comprises about 5 to 125 mg/kg of heparin and about 5 to 500 mg/kg of the delivery agent compound, or the composition comprises about 0.25 to 10 mg/kg of recombinant human growth hormone and about 50 to 500 mg/kg of the delivery agent compound, or the composition comprises about 0.1 to 10 mg/kg of leutinizing-hormone-releasing hormone and about 50 to 500 mg/kg of the delivery agent compound, or the composition comprises about 5 to 125 mg/kg of caspofungin acetate and about 50 to 500 mg/kg of the delivery agent compound. 9. A method for administering a biologically-active agent to an animal in need of the agent, the method comprising administering orally to the animal the pharmaceutical composition of claim 1. 10. A method of treating a disease in an animal characterized by hyperglycemia, comprising administering to the animal the pharmaceutical composition of claim 1. 11. A method of treating a disease in an animal characterized by intravascular thrombi or deep vein thrombosis, comprising administering to the animal the pharmaceutical composition of claim 1, wherein the biologically active agent is heparin. 12. A method of treating or preventing short stature in a subject, comprising administering to the subject the pharmaceutical composition of claim 1, wherein the biologically active agent is recombinant human growth hormone. 13. A method of treating a disease that requires supplementation of growth hormone or leutenizing-hormone-releasing hormone, comprising administering to a subject in need thereof the pharmaceutical composition of claim 1, wherein the biologically active agent is leutenizing-hormone-releasing hormone. 14. A method of treating or preventing infertility in men or women that requires supplementation of leutenizing-hormone-releasing hormone, comprising administering to a subject in need thereof the pharmaceutical composition of claim 1, wherein the biologically active agent is leutenizing-hormone-releasing hormone. 15. A method of treating candidiasis, comprising administering to a subject in need thereof the pharmaceutical composition of claim 1, wherein the biologically active agent is caspofungin acetate. 16. A method of increasing the bioavailability of a pharmaceutical composition containing an a biologically an active agent selected from proteins, polypeptides, peptides, hormones, polysaccharides, mucopolysaccharides, carbohydrates, and lipids, comprising adding at least one delivery agent compound of claim 1 to the pharmaceutical composition. 17. A method for preparing a pharmaceutical composition of claim 1 comprising mixing: (A) at least one biologically active agent selected from proteins, polypeptides, peptides, hormones, polysaccharides, mucopolysaccharides, carbohydrates, and lipids; (B) at least one said delivery agent; and (C) optionally, a dosing vehicle.

Details for Patent 8,466,199

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Eli Lilly And Company	HUMULIN R U-100	insulin human	Injection	018780	10/28/1982		2027-03-21
Eli Lilly And Company	HUMULIN R U-500	insulin human	Injection	018780	12/29/2015		2027-03-21
Eli Lilly And Company	HUMULIN R U-100	insulin human	Injection	018780	08/06/1998		2027-03-21
Eli Lilly And Company	HUMULIN R U-500	insulin human	Injection	018780	03/31/1994		2027-03-21
Eli Lilly And Company	HUMULIN R U-100	insulin human	Injection	018780	05/25/2018		2027-03-21